二至天癸方改善卵巢储备功能减退患者IVF-ET结局的临床疗效与药理机制
该随机安慰剂对照试验纳入120例接受IVF-ET的DOR患者,二至天癸方组优质胚胎数量和率显著高于安慰剂组(P<0.05),但妊娠结局无统计学差异(P>0.05)。细胞实验提示该方部分通过调控NEAT1/miR-10b-3p/FOXO3a通路抑制卵巢颗粒细胞凋亡。
要点
- 二至天癸方可提高DOR患者IVF-ET中的优质胚胎数量和率。
- 该方对妊娠结局未见统计学显著改善。
- 机制可能涉及调控NEAT1/miR-10b-3p/FOXO3a通路。
核心结论
- 二至天癸方治疗可提高DOR患者IVF-ET的胚胎质量,部分归因于调控NEAT1/miR-10b-3p/FOXO3a通路。
研究设计与样本
- 随机安慰剂对照试验,纳入2021年3月至12月山东中医药大学附属医院120例接受IVF-ET的DOR患者,EZTGF组60例、安慰剂组60例。
- 所有参与者采用促性腺激素释放激素拮抗剂方案控制性卵巢刺激,干预自前一月经周期第2-3天开始至扳机日。
- 机制研究使用KGN细胞,双荧光素酶报告基因实验确认NEAT1、miR-10b-3p与FOXO3a的调控关系。
主要发现
- 116例完成试验(每组58例)。
- EZTGF组优质胚胎数量(尤其在卵裂期)和率均较安慰剂组显著增加(P<0.05)。
- 妊娠结局组间无统计学显著差异(P>0.05)。
- 细胞实验显示miR-10b-3p抑制OGC增殖并促进凋亡。
- 双荧光素酶报告基因实验确认NEAT1与miR-10b-3p、miR-10b-3p与FOXO3a的靶向调控关系。
临床怎么用
- 对于接受IVF-ET的DOR患者,可考虑在拮抗剂方案促排卵周期中联合二至天癸方以改善优质胚胎数量和质量。
- 该方对妊娠结局的改善尚不明确,临床决策需结合患者具体情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the efficacy of the Er Zhi Tian Gui Formula (EZTGF) in diminished ovarian reserve (DOR) patients undergoing in vitro fertilization-embryo transfer (IVF-ET); to examine the pharmacological mechanism of EZTGF in inhibiting ovarian granulosa cell (OGC) apoptosis. METHODS: A total of 120 DOR patients undergoing IVF-ET in the Affiliated Hospital of Shandong University of TCM from March to December 2021 were randomly assigned to the EZTGF (n = 60) or Placebo (n = 60) groups. All participants followed a gonadotropin-releasing hormone antagonist protocol for controlled ovarian stimulation, with interventions starting on days 2-3 of the preceding menstrual cycle and continuing until the trigger day. IVF-ET outcomes measured included the number of oocytes retrieved, embryo quality, and pregnancy rates. NEAT1, miR-10b-3p, and FOXO3a OGCs expression was analyzed via qRT-PCR. Mechanistic studies were conducted using KGN cells, with dual-luciferase reporter assays confirming regulatory relationship between NEAT1, miR-10b-3p, and FOXO3a. RESULTS: A total of 116 patients completed the trial (58 in each group). The EZTGF group showed a significant increase in both the number (especially at the cleavage stage) and rate of high-quality embryos, compared with the Placebo group (P < 0.05). No statistically significant differences in pregnancy outcomes were observed (P > 0.05). Cellular experiments showed that miR-10b-3p inhibits proliferation and promotes apoptosis in oocyte granulosa cells (OGCs). Dual luciferase reporter gene assay confirms target-regulatory relationship of NEAT1 with miR-10b-3p, miR-10b-3p and FOXO3a. EZTGF treatment partially reversed the low expression of NEAT1 and FOXO3a, and the high expression of miR-10b-3p in OGCs from DOR patients. CONCLUSION: Treatment with EZTGF enhances embryo quality in women with DOR undergoing IVF-ET, which can be partially attributed to modulation of the NEAT1/miR-10b-3p/FOXO3a pathway. Trial registration: ChiCTR2100052522.
引用
- Chen W, Lian F, Song J, et al. Clinical efficacy and pharmacological mechanism of Er Zhi Tian Gui formula in enhancing IVF-ET outcomes for diminished ovarian reserve. Front Pharmacol. 2025. PMID: 40191422. doi:10.3389/fphar.2025.1552581
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。